BioMEMS firm Proteus raises $5.3 million

Jan. 21, 2004 — Proteus Biomedical, a Menlo Park, Calif., developer of MEMS devices to treat congestive heart failure, raised $5.3 million in a Series B round of financing, according to the company’s chief executive. The company’s Series A was a seed round.


Adams Street Partners led the financing. Asset Management Partners, Fletcher Spaght Ventures and Spring Ridge Ventures also participated.


Andrew Thompson, Proteus’ CEO, said the company is developing systems composed of circuits, sensors and actuators to enable heart failure therapies. Thompson said physicians could treat problems that cause heart failure more effectively if they had sophisticated feedback from patients.


Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.